bioasis Technologies Inc.  

(Public, CVE:BTI)   Watch this stock  
Find more results for cve:bti
+0.01 (0.88%)
Jan 29 - Close
CVE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 1.08 - 1.18
52 week 0.67 - 1.35
Open 1.08
Vol / Avg. 55,100.00/70,820.00
Mkt cap 50.64M
P/E     -
Div/yield     -
EPS -0.08
Shares 44.03M
Beta 0.61
Inst. own     -

Key stats and ratios

Q3 (Aug '14) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -94.12% -112.57%
Return on average equity -98.70% -120.64%
CDP Score - -


Suite 125, 10551 Shellbridge Way
+1-778-3833280 (Phone)
+1-604-2150091 (Fax)

Website links


biOasis Technologies Inc. is an early stage biopharmaceutical company focused on research, development and commercialization of technologies and products intended for diagnosis and treatment of central nervous system (CNS) diseases and other disorders located within the brain. As of February 29, 2012, the Company was engaged in the development of a vector (Transcend) for the transport of therapeutic agents across the blood brain barrier (BBB), and the development of an in vitro diagnostic assay to assist physicians in diagnosis of Alzheimer�s disease (Cognitest). During the fiscal year ended February 29, 2012 (fiscal 2012), SISCAPA Assay Technologies, Inc., refined and streamlined the SISCAPA assay for p97. SISCAPA assays are being used as an analytical reference for the samples being evaluated in the Cognitest program.

Officers and directors

Robin B. Hutchison Chairman of the Board, President, Chief Executive Officer
Age: 58
Judi Dalling Chief Financial Officer, Corporate Secretary
Ronald P. Erickson Independent Director
Age: 70
H. Christian Fibiger P.hD. Independent Director
Age: 71
Greg D. Gubitz Independent Director
Age: 57
J. Michael Hutchison QC Independent Director
Age: 70
Terry Pearson Ph.D. Independent Director
Age: 68